| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $559,848 ) |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045724 | Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | 000 | 5 | NIH | 1/8/2024 | $503,863 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045724 | Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | 001 | 5 | NIH | 4/25/2024 | $55,985 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA058674 | A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting | 000 | 1 | NIH | 2/2/2024 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG3DA058305 | Continuing Care App for Justice-Involved Individuals with Substance Use Disorders | 000 | 1 | NIH | 10/23/2023 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA043476 | Buprenorphine for probationers and parolees: Bridging the gap into treatment | 000 | 5 | NIH | 4/4/2024 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R61DA059033 | Implementing a patient navigation intervention across a health system to address treatment entry inequities | 000 | 1 | NIH | 12/8/2023 | $0 |
| | 2024 | 2021 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA040636 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 5 | NIH | 4/8/2024 | $0 |
| | 2024 | 2021 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | U01DA046910 | Facilitating the Implementation of Interim Methadone to Increase Treatment Access: A Multi-Site Implementation Trial | 000 | 4 | NIH | 11/29/2023 | $0 |
| | 2024 | 2020 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R21DA047580 | People Preferring Fentanyl (PPF): Characteristics, Outcomes, and Perspectives | 000 | 2 | NIH | 1/23/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $8,708,120 ) |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 5 | NIH | 4/28/2023 | $1,967,149 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression | 000 | 1 | NIH | 8/11/2023 | $636,993 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057052 | Scope and impact of methadone take-home and telehealth practice changes during the COVID-19 pandemic | 001 | 2 | NIH | 6/29/2023 | $628,884 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R61DA059033 | Implementing a patient navigation intervention across a health system to address treatment entry inequities | 000 | 1 | NIH | 9/21/2023 | $946,763 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA058674 | A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting | 000 | 1 | NIH | 9/15/2023 | $881,830 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045724 | Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | 000 | 4 | NIH | 1/30/2023 | $688,020 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA043476 | Buprenorphine for probationers and parolees: Bridging the gap into treatment | 000 | 5 | NIH | 4/20/2023 | $562,665 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA055532 | Intervention to Reduce Internalized Stigma (IRIS) among People Living with HIV who use Substances | 001 | 2 | NIH | 8/1/2023 | $275,802 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG3DA058305 | Continuing Care App for Justice-Involved Individuals with Substance Use Disorders | 000 | 1 | NIH | 5/15/2023 | $573,506 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substance Use Disorder | 001 | 2 | NIH | 7/27/2023 | $908,730 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R21MH130271 | Development and Testing of an Identity Measure for Transgender and Gender Diverse Persons | 001 | 2 | NIH | 8/22/2023 | $193,686 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 002 | 5 | NIH | 9/14/2023 | -$444,092 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 002 | 5 | NIH | 9/14/2023 | $444,092 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 001 | 5 | NIH | 5/1/2023 | $444,092 |
| | 2023 | 2022 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substance Use Disorder | 000 | 1 | NIH | 11/17/2022 | $0 |
| | 2023 | 2022 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057052 | Scope and impact of methadone take-home and telehealth practice changes during the COVID-19 pandemic | 000 | 1 | NIH | 12/23/2022 | $0 |
| | 2023 | 2022 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057608 | Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology | 000 | 1 | NIH | 1/27/2023 | $0 |
| | 2023 | 2022 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA055532 | Intervention to Reduce Internalized Stigma (IRIS) among People Living with HIV who use Substances | 000 | 1 | NIH | 11/17/2022 | $0 |
| | 2023 | 2022 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R21MH130271 | Development and Testing of an Identity Measure for Transgender and Gender Diverse Persons | 000 | 1 | NIH | 12/28/2022 | $0 |
| | 2023 | 2021 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA040636 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 5 | NIH | 3/28/2023 | $0 |
| | 2023 | 2020 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | H9731807 | Special Projects of National Significance | 04 | 3 | HRSA | 8/16/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $9,766,742 ) |
| | 2022 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045562 | Getting Off: A Theory-based mHealth Intervention for Methamphetamine-using MSM | 000 | 5 | NIH | 4/15/2022 | $413,895 |
| | 2022 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA043476 | Buprenorphine for probationers and parolees: Bridging the gap into treatment | 000 | 4 | NIH | 4/15/2022 | $627,397 |
| | 2022 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057608 | Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology | 000 | 1 | NIH | 9/20/2022 | $2,254,579 |
| | 2022 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057685 | Identifying Suspected Drug Overdose Deaths in Near Real-Time Using Data Collected by Death Investigators | 000 | 1 | NIH | 9/20/2022 | $2,099,989 |
| | 2022 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA055532 | Intervention to Reduce Internalized Stigma (IRIS) among People Living with HIV who use Substances | 000 | 1 | NIH | 8/31/2022 | $212,136 |
| | 2022 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R21MH130271 | Development and Testing of an Identity Measure for Transgender and Gender Diverse Persons | 000 | 1 | NIH | 9/6/2022 | $178,781 |
| | 2022 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substance Use Disorder | 000 | 1 | NIH | 8/26/2022 | $594,260 |
| | 2022 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 002 | 4 | NIH | 9/14/2022 | $678,563 |
| | 2022 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 001 | 4 | NIH | 4/30/2022 | $2,169,367 |
| | 2022 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057052 | Scope and impact of methadone take-home and telehealth practice changes during the COVID-19 pandemic | 000 | 1 | NIH | 9/15/2022 | $537,775 |
| | 2022 | 2021 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | U01DA046910 | Facilitating the Implementation of Interim Methadone to Increase Treatment Access: A Multi-Site Implementation Trial | 000 | 4 | NIH | 5/25/2022 | $0 |
| | 2022 | 2021 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045724 | Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | 000 | 3 | NIH | 1/20/2022 | $0 |
| | 2022 | 2021 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 3 | NIH | 10/25/2021 | $0 |
| | 2022 | 2021 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 3 | NIH | 10/25/2021 | $0 |
| | 2022 | 2021 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | U01DA046910 | Facilitating the Implementation of Interim Methadone to Increase Treatment Access: A Multi-Site Implementation Trial | 000 | 4 | NIH | 5/25/2022 | $0 |
| | 2022 | 2020 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R21DA047580 | People Preferring Fentanyl (PPF): Characteristics, Outcomes, and Perspectives | 000 | 2 | NIH | 6/15/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $5,471,238 ) (Continued on the next page) |
|
